Your provider can explain trade-offs based on your goals and medical history
In laboratory research, administering 5-Amino-1MQ competitively inhibits NNMT activity, halting the clearance of nicotinamide
Semaglutide is contraindicated in patients with a personal or family history of certain types of thyroid cancer, specifically thyroid C-cell tumors such as medullary thyroid carcinoma (MTC), or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2)
Tirzepatide follows similar escalation patterns, starting at 2.5mg weekly and increasing to 5mg, 7.5mg, 10mg, 12.5mg, or 15mg based on tolerance and response
First, semaglutide activates GLP-1 receptors in the brain, particularly in the hypothalamus, which reduces appetite and changes how you experience hunger